385 related articles for article (PubMed ID: 1350343)
1. Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
Nakshabendi IM; Duncan A; Russell RI
Postgrad Med J; 1992 Mar; 68(797):189-91. PubMed ID: 1350343
[TBL] [Abstract][Full Text] [Related]
2. Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.
Faber SM; Korelitz BI
J Clin Gastroenterol; 1993 Oct; 17(3):213-8. PubMed ID: 8228082
[TBL] [Abstract][Full Text] [Related]
3. Mesalazine in childhood inflammatory bowel disease.
Barden L; Lipson A; Pert P; Walker-Smith JA
Aliment Pharmacol Ther; 1989 Dec; 3(6):597-603. PubMed ID: 2577501
[TBL] [Abstract][Full Text] [Related]
4. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Rachmilewitz D
BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951
[TBL] [Abstract][Full Text] [Related]
5. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Ardizzone S; Petrillo M; Imbesi V; Cerutti R; Bollani S; Bianchi Porro G
Aliment Pharmacol Ther; 1999 Mar; 13(3):373-9. PubMed ID: 10102971
[TBL] [Abstract][Full Text] [Related]
6. The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
Donald IP; Wilkinson SP
Postgrad Med J; 1985 Dec; 61(722):1047-8. PubMed ID: 2869480
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
Rutgeerts P
Aliment Pharmacol Ther; 1989 Apr; 3(2):183-91. PubMed ID: 2577483
[TBL] [Abstract][Full Text] [Related]
8. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
Martin F
Dig Dis Sci; 1987 Dec; 32(12 Suppl):57S-63S. PubMed ID: 2891469
[TBL] [Abstract][Full Text] [Related]
9. 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Stretch GL; Campbell BJ; Dwarakanath AD; Yaqoob M; Stevenson A; Morris AI; Rhodes JM
Aliment Pharmacol Ther; 1996 Dec; 10(6):941-7. PubMed ID: 8971292
[TBL] [Abstract][Full Text] [Related]
10. The effect of mesalamine and nicotine in the treatment of inflammatory bowel disease.
Bonapace CR; Mays DA
Ann Pharmacother; 1997; 31(7-8):907-13. PubMed ID: 9220055
[TBL] [Abstract][Full Text] [Related]
11. [Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
Feurle GE; Helmstädter V
Dtsch Med Wochenschr; 1986 May; 111(18):721-2. PubMed ID: 2870908
[No Abstract] [Full Text] [Related]
12. [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
Maier K; Fischer C; Klotz U; Heinkel K
Dtsch Med Wochenschr; 1982 Jul; 107(29-30):1131-4. PubMed ID: 6123426
[TBL] [Abstract][Full Text] [Related]
13. Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Prakash A; Markham A
Drugs; 1999 Mar; 57(3):383-408. PubMed ID: 10193690
[TBL] [Abstract][Full Text] [Related]
14. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA
Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536
[TBL] [Abstract][Full Text] [Related]
15. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
Thomson AB
Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778
[TBL] [Abstract][Full Text] [Related]
16. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease.
Brogden RN; Sorkin EM
Drugs; 1989 Oct; 38(4):500-23. PubMed ID: 2684592
[TBL] [Abstract][Full Text] [Related]
17. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
18. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. International Mesalazine Study Group.
Aliment Pharmacol Ther; 1990 Feb; 4(1):55-64. PubMed ID: 2104074
[TBL] [Abstract][Full Text] [Related]
19. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
Andreoli A; Spinella S; Levenstein S; Prantera C
Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
[TBL] [Abstract][Full Text] [Related]
20. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
Ann Intern Med; 1996 Jan; 124(2):204-11. PubMed ID: 8533995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
